. Author manuscript; available in PMC: 2014 Aug 7.

Published in final edited form as: Blood Rev. 2013 Jul 27;27(5):243–259. doi: 10.1016/j.blre.2013.07.003

Table 4.

Factors reported in the literature to be associated with clinical responses to immunosuppressive therapy in patients with myelodysplastic syndromes (MDS).

Age (<60 years)

Early stage MDS (FAB RA and IPSS low and INT-1)

HLA-DR15+ Status

Trisomy 8 karyoptype

Female gender

Short duration of RBC transfusion dependency

Lower RBC transfusion requirements

Presence of a PNH clone

BM hypocellularity

FAB: French-American-British classification; RA: Refractory anemia; IPSS: International Prognostic Scoring System; INT-1: Intermediate-1; HLA: Human leukocyte antigen; RBC: Red blood cells; PNH: Paroxysmal nocturnal hemoglobinuria; BM: Bone marrow. Data from Refs. [97–113].